Drug Discovery for Ion Channels XV

Friday, February 6, 2015
Baltimore Convention Center
Room 307/308

8:00 AM: Registration Opens
8:30 AM: Program Begins
12:00 PM - 1:00 PM: Lunch (provided)
5:15 PM: Program Ends

Onsite registration will be available.

Ion channels are an important class of therapeutic drug targets, and mutations in ion channel genes are found to be responsible for an increasing number of diseases. While conventional electrophysiological techniques permit the most detailed and direct study of ion channel function, they are limited due to the manual nature of the method and their low throughput. Because of this, ion channels remain an underrepresented target class for drug discovery. The advent of higher throughput automated electrophysiology systems has begun to change the face of ion channel drug discovery. This symposium will review the advances in automated electrophysiology and other emerging technologies and their impact on ion channel drug discovery today. This year’s meeting will highlight presentations from users of automated electrophysiology instrumentation as well as other speakers in the field of ion channel drug discovery.


8:00 AM - 8:30 AM

Session I, Chair: Morten Sunesen 

8:30 AM - 9:00 AM

Keynote Speaker: David Fedida, University of British Columbia, Canada
Ion Channel Blockers as Therpeautics for Atrial Fibrillation: From Theory into Practice

9:00 AM - 9:30 AM

Haiyang (David) Wei, EuroFins, USA
Evaluation and Validation of a High-throughput, Microfluidic Patch Clamp System for Ligand- and Voltage-gated Ion Channels Compound Screening and Profiling

9:30 AM - 10:00 AM 

Stephen Hess, Evotec, Germany
Use of a High Fidelity 384 Channel Gigaseal APC in a CRO Setting

10:00 AM - 10:30 AM 

Session II, Chair: Chris Mathes 

10:30 AM - 11:00 AM 

Andrew D Penman, Southern Research
Preparing for CIPA – Cell Biology and Beyond

11:00 AM - 11:30 AM

Natali Minassian, Pfizer Inc, USA
Optimizing Screening Strategies for NMDARs

11:30 AM - 12:00 PM 

Heike Wulff, University of California, Davis, USA
Microglial Kv1.3 and KCa3.1 as Targets for Neuroinflammation

12:00 PM - 1:00 PM 

Break (lunch provided)
Session III, Chair: Niels Fertig 

1:00 PM - 1:30 PM 

Keynote Speaker: Christine Colvis, NIH/NCATS, USA
Illuminating the Druggable Genome: Moving the Lamppost to Look for New Targets

1:30 PM -  2:00 PM 

Glenn Kirsch, Chantest, USA
Ligand-gated Ion Channel Screening and Profiling using ScreenPatch Technologies

2:00 PM - 2:30 PM

Juha Kammonen, Neusentis, United Kingdom
Application of True High Throughput, High Quality APC Platform in Drug Discovery Screening Programs

2:30 PM - 3:00 PM 

Daniel Hochbaum, Q-State Biosciences, USA
All-optical Electrophysiology 

3:00 PM - 3:30 PM B


Session IV, Chair: Jim Costantin 

3:30 PM - 4:00 PM 

Alfred L. George, Northwestern University, USA
Voltage-gated Sodium Channel Biophysics on 384-well HTS Patch Clamp Platform

4:00 PM - 4:30 PM 

Jean-Sébastien Rougier, University of Bern, Switzerland
Late Sodium Current in the Drug Screening Process: The Challenge of the Automated Patch-Clamp

4:30 PM - 5:00 PM 

Arthur "Buzz" Brown, ChanTest, USA
The Role of Human Stem Cell-Derived Cardiomyocytes as Predictors of Drug Efficacy & Safety

5:00 PM - 5:15 PM C

losing Remarks, Chris Mathes

Sponsored by: